Mannose-Functionalized Nanoscaffolds for Targeted Delivery in Biomedical Applications
- PMID: 30251341
- DOI: 10.1002/asia.201801088
Mannose-Functionalized Nanoscaffolds for Targeted Delivery in Biomedical Applications
Abstract
Targeted drug delivery by nanomaterials has been extensively investigated as an effective strategy to surmount obstacles in the conventional treatment of cancer and infectious diseases, such as systemic toxicity, low drug efficacy, and drug resistance. Mannose-binding C-type lectins, which primarily include mannose receptor (MR, CD206) and dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), are highly expressed on various cancer cells, endothelial cells, macrophages, and dendritic cells (DCs), which make them attractive targets for therapeutic effect. Mannosylated nanomaterials hold great potential in cancer and infection treatment on account of their direct therapeutic effect on targeted cells, modulation of the tumor microenvironment, and stimulation of immune response through antigen presentation. This review presents the recent advances in mannose-based targeted delivery nanoplatforms incorporated with different therapies in the biomedical field.
Keywords: cancer; drug delivery; gene therapy; mannose receptors; nanostructures.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
-
Selective targeting of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) with mannose-based glycomimetics: synthesis and interaction studies of bis(benzylamide) derivatives of a pseudomannobioside.Chemistry. 2013 Apr 8;19(15):4786-97. doi: 10.1002/chem.201202764. Epub 2013 Feb 18. Chemistry. 2013. PMID: 23417900
-
Comparative analysis reveals selective recognition of glycans by the dendritic cell receptors DC-SIGN and Langerin.Protein Eng Des Sel. 2011 Sep;24(9):659-69. doi: 10.1093/protein/gzr016. Epub 2011 May 2. Protein Eng Des Sel. 2011. PMID: 21540232
-
Mannose hyperbranched dendritic polymers interact with clustered organization of DC-SIGN and inhibit gp120 binding.FEBS Lett. 2006 May 1;580(10):2402-8. doi: 10.1016/j.febslet.2006.03.061. Epub 2006 Mar 31. FEBS Lett. 2006. PMID: 16616922
-
Mannosylated Constructs as a Platform for Cell-Specific Delivery of Bioactive Agents.Crit Rev Ther Drug Carrier Syst. 2018;35(2):157-194. doi: 10.1615/CritRevTherDrugCarrierSyst.2018020313. Crit Rev Ther Drug Carrier Syst. 2018. PMID: 29717665 Review.
-
Mannose-targeted systems for the delivery of therapeutics.Expert Opin Drug Deliv. 2008 Jun;5(6):703-24. doi: 10.1517/17425247.5.6.703. Expert Opin Drug Deliv. 2008. PMID: 18532925 Review.
Cited by
-
Mannose Receptor-Mediated Carbon Nanotubes as an Antigen Delivery System to Enhance Immune Response Both In Vitro and In Vivo.Int J Mol Sci. 2022 Apr 11;23(8):4239. doi: 10.3390/ijms23084239. Int J Mol Sci. 2022. PMID: 35457058 Free PMC article.
-
A Stable Gold Nanoparticle-Based Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens.ACS Bio Med Chem Au. 2021 Dec 15;1(1):31-43. doi: 10.1021/acsbiomedchemau.1c00021. Epub 2021 Sep 10. ACS Bio Med Chem Au. 2021. PMID: 34927166 Free PMC article.
-
Mannose: A Promising Player in Clinical and Biomedical Applications.Curr Drug Deliv. 2024;21(11):1435-1444. doi: 10.2174/0115672018275954231220101637. Curr Drug Deliv. 2024. PMID: 38310442 Review.
-
Applications of mannose-binding lectins and mannan glycoconjugates in nanomedicine.J Nanopart Res. 2022;24(11):228. doi: 10.1007/s11051-022-05594-1. Epub 2022 Nov 4. J Nanopart Res. 2022. PMID: 36373057 Free PMC article. Review.
-
Advances in the Immunomodulatory Properties of Glycoantigens in Cancer.Cancers (Basel). 2022 Apr 7;14(8):1854. doi: 10.3390/cancers14081854. Cancers (Basel). 2022. PMID: 35454762 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources